ClinicalTrials.gg
Status unknownNCT04354116Updated Sep 16, 2020

MARPE in Patients With Cleft Lip and Palate

An interventional study of Rapid maxillary expansion and Maxillary Protraction in Palatal Expansion Technique, Cleft Lip and Palate and Class III Malocclusion, sponsored by Pontifícia Universidade Católica de Minas Gerais. Status unknown at 1 site in Brazil. Open to participants aged 6 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Pontifícia Universidade Católica de Minas Gerais · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
6 Years to 13 Years
Sex
All
01

Study summary

The objective of this randomized controlled study will be to evaluate the dental and skeletal effects of maxillary protraction with a facemask, associated with MARPE and Class III elastics in patients with unilateral cleft lip and palate (CLP) with maxillary retrusion, compared to HYRAX type maxillary expanders. The investigators will examine differences in treatment times, along with skeletal, dental and soft tissue changes.

Read the detailed description

The CONSORT statement will be used as a guide for this study. This work will be a parallel group study, randomized, with active control, with an allocation ratio of 1: 1.

This study was submitted to the Research Ethics Committee of the Pontifical Catholic University of Minas Gerais. Participants will be recruited in the Master's Degree in Orthodontics at PUC Minas, based on inclusion criteria.

Interventions:

Palatal expanders of the HYRAX type, with bands on the first permanent molars or second deciduous molars will be used for patients in both groups. The hooks for the use of Class III elastics will be welded on the vestibular of the upper molar bands. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control group will be active, with conventional dento-mucus-supported HYRAX expanders. All expanders will be manufactured by the same orthodontic technician.

Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day). The direction of the elastics for the maxillary traction force will be between 15˚ to 30˚ below the occlusal plane, providing a force between 400 and 500 g per side. During the day (12 hours a day), patients will use a lower expansion plate with an occlusal stop, which will be activated once a week (0.25 mm), with hooks in the region of the lower canines for the use of Class III elastics. size 3/16 "(150g). The time-frame of the experiment will be 6 months.

Results (primary and secondary) The primary outcome will be the degree of anterior movement of the maxilla after treatment). Secondary outcomes will be changes in other cephalometric variables and treatment time.

Conical beam computed tomography (CBCT) will be performed at the beginning and at the end of the treatment. Teleradiographies will be extracted from the CFFCs and cephalometric measurements will be obtained by the investigator (V.E.) using the Dolphin Image software (Austin, USA). Traditional cephalometric measurements will be used to describe the changes before and after treatment.

Calculation of the sample size As no study in the orthodontic literature used the same protocol used in this study, the sample size will be estimated by G * Power (version 3.0.8), with 95% power; significance level of 5%; two-tailed. For point A, sagittal movements of 2.6 +/- 1.5 mm in the RME group and 5.8 +/- 2.3 mm in the RME group with constriction, a minimum sample size of 11 in each group will be necessary to detect a significant difference between groups. For ANS, sagittal movements of 2.1 +/- 1.3 mm in the RME group and 4.8 +/- 2.5 mm in the RME group with constriction, a minimum sample size of 16 in each group will be necessary to detect a significant difference between groups. Therefore, 16 will be the minimum sample size for each group. The sample size will be increased by 40%, resulting in 22 patients for each group, in case there is a withdrawal or the need to use a different protocol.

Randomization (random number generation, allocation hiding, implementation) Patients will be recruited and allocated to the control group (RME) or the intervention group (MARPE) according to the sequence of participation. Simple randomization will be applied.

Blinding The blinding of investigators or participants will not be possible because the expanders in the two groups will be different. Operators and patients will easily know which group they are in. However, blinding will be used during cephalometric analysis. All image exams will be hidden by opaque tape and replaced with research numbers and then mixed together before analysis. The investigator will not know the clustering of the CT scans, which will look similar.

Statistical analysis (primary and secondary results, subgroup analyzes) All statistical analyzes will be performed using the software (version 18.0; PASW Statistics, Chicago, Illinois). Descriptive statistics will include the means and standard deviations of age, total treatment time, maxillary prostration time, cephalometric values and changes in values in each group. The 1-sample Kolmogorov-Smirnov test will be used to test the normality of distributions for all times and differences in cephalometric values. Independent t-tests will be used to compare the two groups, including total treatment time, protraction time and changes in cephalometric values; the t-tests will be used for the values that show "equality of variances not assumed" between the groups (SNA and Nasio perpendicular). The level of significance will be 0.05, with two-tailed test.

Error of the Method All locations and measurements of the points will be checked twice carefully at the end of the initial plots and measurements. Not all images will be traced twice. However, to evaluate the tracing errors, 20 scans will be chosen at random. Plots, locations and measurements will be made twice, two weeks apart and then subjected to the Dahlberg formula. The error of the method will be determined by the Dahlberg formula, where n = 20 and d will be the difference between the measurements in 2 moments.

02

Conditions studied

  • Palatal Expansion Technique
  • Cleft Lip and Palate
  • Class III Malocclusion
  • Skeletal Malocclusion

Keywords

  • palatal expansion technique
  • Cleft Lip
  • Cleft Palate
  • Maxillary retroposition
03

In context

Cleft Lip

168 studies on the registry are indexed under Cleft Lip; 51 are open to participants now.

This study's planned enrollment of 44 is above the median of 30 across 116 interventional studies indexed under Cleft Lip.

Browse Cleft Lip studies →

Lead sponsor

Pontifícia Universidade Católica de Minas Gerais is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with cleft lip and palate;
  • 6 to 13 years before orthodontic treatment, with sagittal deficiency of the facial middle third;
  • Angle Class III malocclusion, or mesial step of the deciduous second molars, and anterior crossbite;
  • ANB less than 0˚, Wits less than -2 mm and the distance from point A to the perpendicular nasion less than 0 mm.

Exclusion criteria

Exclusion Criteria:

  • Previous orthodontic treatment;
  • Other craniofacial anomalies;
  • Inadequate maxillary denture for placement of a expander.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    MARPE

    Maxillary expander anchored in mini-implants (MARPE)

    Device: Rapid maxillary expansion · Device: Maxillary Protraction

  • Active comparator
    Hyrax

    Tooth-born anchored maxillary expanders, without mini-implants

    Device: Rapid maxillary expansion · Device: Maxillary Protraction

Interventions

  • DeviceRapid maxillary expansion

    Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.

  • DeviceMaxillary Protraction

    Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).

06

What researchers measure

Primary outcomes

  1. The primary outcome will be the degree of anterior movement of the maxilla after treatment).

    Cone beam computed tomography (CBCT) will be performed at the beginning and at the end of the treatment. Three-dimensional virtual models, built from the CBCT's scans, will allow to measure the changes between T0 and T1. The processing of the TCFC and virtual models will be done using the ITK-SNAP 2.2 software (free software, www.itksnap.org), SLICER CMF 4.0 (free software, www.slicer.org).

    Time frame: 6 months

Secondary outcomes

  1. Secondary outcomes will be changes in other cephalometric variables and treatment time.

    Cone beam computed tomography will be performed at the beginning and at the end of the treatment. Three-dimensional virtual models, built from the CBCT's scans, will allow to measure the changes between T0 and T1. The processing of the TCFC and virtual models will be done using the ITK-SNAP 2.2 software (free software, www.itksnap.org), SLICER CMF 4.0 (free software, www.slicer.org).

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Pontifical Catholic University of Minas Gerais
    Belo Horizonte, MG 30535-901, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Sep 2021, 20 months after the start.

Of 64 non-industry interventional studies with no phase under Cleft Lip, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 33. This study's planned 20 months is close to that.

Counting every sponsor, half of 65 studies reached it within 22 months; a quarter within 15 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 21, 2020
StartActual
Jan 10, 2020
Primary completionEst.
Sep 10, 2021
CompletionEst.
Sep 10, 2021
Last update
Sep 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04354116
Lead sponsor
Pontifícia Universidade Católica de Minas Gerais
Responsible party
Ildeu Andrade Jr. (Principal Investigator, Pontifícia Universidade Católica de Minas Gerais) — Principal investigator
First posted
Apr 21, 2020
Start date
Jan 10, 2020
Primary completion
Sep 10, 2021 (estimated)
Completion
Sep 10, 2021 (estimated)
Last update
Sep 16, 2020

Study contacts

Vitor Eto, DDS
Contact
ildeu_andrade@yahoo.com.br
55(31)99822-5804
Ildeu Andrade Jr., PhD
principal investigator · Pontifícia Universidade Católica de Minas Gerais

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion